2022 AHA/ACC Guidelines for Diagnosis and Management of Aortic Disease

Rita Weise MSN, ACNPC-AG

Nurse Practitioner Supervisor Matranga Aortic Center and Marfan and Associated Conditions Clinic Hoag Memorial Hospital, Newport Beach CA

5th Annual Houston Aortic Nursing Symposium May 15, 2023

For Internal Use Only – Not for External Distribution. This document is the property of Hoag and includes proprie







5th Annual Houston Aortic Nursing Symposium March 15, 2023 • 12:00 – 5:00 PM



hoag Jeffrey M. Carlton Heart & Vascular Institute

Goals of aortic update

1) Know the class of recommendations and levels of evidence

2) What is a multidisciplinary aortic team

3) Shared decision making

4) When to utilize genetic testing

5) Surgical size guidelines

6) Medical Management Acute and Long-term



ACCF/AHA GUIDELINE

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine

2014 ESC Guidelines on the diagnosis and treatment of aortic diseases

Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult

The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)

Position Statement

Canadian Cardiovascular Society Position Statement on the Management of Thoracic Aortic Disease

2021 The American Association for Thoracic Surgery expert consensus document: Surgical treatment of acute type A aortic dissection

CLINICAL PRACTICE GUIDELINE

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease

A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Developed in collaboration with and endorsed by the American Association for Thoracic Surgery, American College of Radiology, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and Society for Vascular Surgery

Endorsed by the Society of Interventional Radiology and Society for Vascular Medicine



Table

Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care



CLASS (STRENGTH) OF RECOMMENDATION		LEVEL (QUALITY) OF EVIDENCE	ŧ
CLASS 1 (STRONG)	Benefit>>> Risk	LEVELA	
Suggested phrases for writing recommendations: Is recommended Is indicated/useful/effective/beneficial 		High-quality evidence‡ from r Meta-analyses of high-quality One or more RCTs corroborate	
 Should be performed/administered/other Comparative-Effectiveness Phrases1: 		LEVEL B-R	(Randomized)
Comparative-Enectiveness Phrases 1: Treatment/strategy A is recommended/indicated in pre Treatment A should be chosen over treatment B	ference to treatment B	 Moderate-quality evidence‡ f Meta-analyses of moderate-quality 	
CLASS 2a (MODERATE)	Benefit>> Risk	LEVEL B-NR	(Nonrandomized)
Suggested phrases for writing recommendations: Is reasonable Can be useful/effective/beneficial			irom 1 or more well-designed, well-executed ervational studies, or registry studies s
Comparative-Effectiveness Phrases†: Treatment/strategy A is probably recommended/indica		LEVEL C-LD	(Limited Data)
 Treatment, strategy A is probably recommended, indica treatment B It is reasonable to choose treatment A over treatment B 	ted in preference to	limitations of design or execu	
CLASS 2b (Weak)	Benefit≥ Risk	Meta-analyses of such studie Physiological or mechanistics	
Suggested phrases for writing recommendations:		LEVEL C-EO	(Expert Opinion)
May/might be reasonable May/might be considered		Consensus of expert opinion I	based on clinical experience.
May/might be considered Usefulness/effectiveness is unknown/unclear/uncertain or n	ot well-established		
CLASS 3: No Benefit (MODERATE)	Benefit = Risk		
Suggested phrases for writing recommendations: Is not recommended Is not indicated/useful/effective/beneficial Should not be performed/administered/other 			
CLASS 3: Harm (STRONG)	Risk > Benefit		
Suggested phrases for writing recommendations: Potentially harmful Causes harm Associated with excess morbidity/mortality 			


of Aortic Disease. Circulation

· Should not be performed/administered/other

Imaging Modalities

CT, MRI & Echo imaging of patients with aortic disease should follow recommended:

- approaches for image acquisition
- measurement and reporting of relevant aortic dimensions
- frequency of surveillance before and after intervention





Aortic Imaging Techniques to Determine Presence and Progression of Aortic Disease

Recom	Recommendations for Aortic Imaging Techniques to Determine Presence and Progression of Aortic			
		Disease		
Refer	enced stud	ies that support the recommendations are summarized in the Online Data Supplement.		
COR	LOE	Recommendations		
1	B-NR	1. In patients with known or suspected aortic disease, aortic diameters should be measured at reproducible anatomic landmarks perpendicular to axis of blood flow, and these measurement methods should be reported in a clear and consistent manner. In cases of asymmetric or oval contour, the longest diameter and its perpendicular diameter should be reported.		
1	C-LD	2. In patients with known or suspected aortic disease, episodic and cumulative ionizing radiation doses should be kept as low as feasible while maintaining diagnostic image quality.		



Aortic Imaging Techniques to Determine Presence and Progression of Aortic Disease



1		٥	
(C(3. In patients with known or suspected aortic disease, when performing CT or MR imaging, it is
-			recommended that the root and ascending aortic diameters be measured from inner-edge to
	1	C-EO	inner-edge, using an electrocardiographic-synchronized technique. If there are aortic wall
			abnormalities, such as atherosclerosis or discrete wall thickening (more common in the distal
			aorta), the outer-edge to outer-edge diameter should be reported (Table 4).
			4. In patients with known or suspected aortic disease, the aortic root diameter should be recorded as
		C-EO	maximum sinus to sinus measurement. In the setting of known asymmetry, multiple
	1	C-EO	measurements should be reported, and both short- and long-axis images of the root should be
			obtained to avoid underestimation of the diameter.
			5. In patients with known or suspected aortic disease, it is reasonable that a dilated root or
	2a	C-LD	ascending aorta be indexed to patient height or BSA in the report, to aid in clinical risk
			assessment.
			6. In patients with known or suspected aortic disease, when performing echocardiography, it is
			reasonable to measure the aorta from leading-edge to leading-edge, perpendicular to the axis of
			blood flow.
	2a		Using inner-edge to inner-edge measurements may also be considered, particularly on short-axis
	24		imaging.
		C-EO	



Multidisciplinary Aortic Teams

Recommen	dations for N	Iultidisciplinary Aortic Teams	
COR	LOE	Recommendations	
1	C-EO	 For patients with acute aortic disease that requires urgent repair, a multidisciplinary team should determine the most suitable interven- tion. 	
2a	C-LD	2. For patients who are asymptomatic with extensive aortic disease, or who may benefit from complex open and endovascular aortic repairs, or with multiple comorbidities for whom intervention is considered, referral to a high-volume center (performing at least 30-40 aortic procedures annually) with experienced surgeons in a Multidisciplinary Aortic Team is reasonable to optimize treatment outcomes. ¹⁻⁶	




JAMA Cardiology | Original Investigation

Early Mortality in Type A Acute Aortic Dissection Insights From the International Registry of Acute Aortic Dissection

Kevin M. Hants, MD; Christoph A. Nienaber, MD; Mark D. Peterson, MD; Elite M. Woznicki, BS-Alan C. Braverman, MD, Santi Trimarchi, MD, PhD; Truls Myrmel, MD, PhD; Reed Pyeritz, MD; Stuart Hutchison, MD, Craig Strauss, MD, Marek P, Ehrlich, MD, Thomas G, Gleason, MS, MD, Amit Korach, MD; Daniel G. Montgomery, BS; Eric M. Isselbacher, MD; Kim A. Eagle, MD

Processes of Care and Aortic Centers

The critical group of patients who die before surgery highlights the importance of processes to rapidly identify AD and move these patients to surgery without delay.³ There are inherent delays in AD recognition and treatment, with times from presentation to diagnosis of 2.5 hours and from diagnosis to surgery of 3.5 hours, totaling 6 hours from emergency department arrival to surgery in IRAD centers.⁹ In the group of patients who died awaiting surgery, the median (IQR) time from presentation to death was 8.9 hours (4-32). Interhospital transfer is needed in more than 70% of cases, leading to inherent treatment delays, and several centers have developed regional transfer processes.^{3,23-31} A regional care model with emphasis on diagnosis and treatment protocols has been shown to reduce times to diagnosis and treatment.23



Annual Center Case Volume Category


JAMA Cardiol.2022: 7(10):109-1015



Shared Decision Making

 C-LD In patients with aortic disease, shared decision-making is recommended when determining the appropriate thresholds for intervention, deciding on the type of surgical repair, choosing between open surgical versus endovascular approaches; and in medical management and surveillance.¹⁻⁶ In patients with aortic disease who are contemplating pregnancy or who are pregnant, shared decision-making is recommended when considering the cardiovascular risks of pregnancy, the diameter thresholds 	COR	LOE	RECOMMENDATIONS
1 C-EO making is recommended when considering the cardiovascular risks of pregnancy, the diameter thresholds	1	C-LD	priate thresholds for intervention, deciding on the type of surgical repair, choosing between open surgical
for prophylactic partic surgeny, and the mode of delivery	i	C-EO	







Eric M. Isselbacher. Circulation. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, Volume: 146, Issue: 24, Pages: e334-e482, DOI: (10.1161/CIR.000000000001106)



When to utilize clinical genetic testing?


Thoracic aortic aneurysm

- Syndromic features
- Dissection/aneurysm before age 60
- FHx of TAD or SCD <50 y</p>
- BAV aortopathy
- FHx of aortic disease or SCD <50 y</p>
- With (minor) syndromic features (10% of LDS with BAV)

"It should be recognized that there is no upper limit of age at which patients present with TAD that precludes an underlying genetic cause of the disease."



Personalized Approach (clinical data, and gene variant)





Acute Aortic Syndrome Medication Management

Recommendations for Acute Medical Management of AAS Referenced studies that support the recommendations are summarized in the Option 2016 Support

COR	LOE	Recommendations
1	B-NR	 In patients presenting to the hospital with AAS, prompt treatment with anti-impulse therapy with invasive monitoring of BP with an arterial line in an ICU setting is recommended as initial treatment to decrease aortic wall stress.¹⁻⁶
1	C-LD	 Patients with AAS should be treated to an SBP <120 mm Hg or to lowest BP that main- tains adequate end-organ perfusion, as well as to a target heart rate of 60 to 80 bpm.³⁶
1	B-NR	 In patients with AAS, initial management should include intravenous beta blockers, except in patients with contraindications.²⁵⁷
2a	B-NR	In those with contraindications or intolerance to beta blockers, initial management with an intravenous non-dihydropyridine calcium channel blocker is reasonable for heart rate control. ¹²⁵
1	C-LD	 In patients with AAS, initial management should include intravenous vasodilators if the BP is not well controlled after initiation of intravenous beta-blocker therapy.[®]
1	C-EO	 Patients with AAS should be treated with pain control, as needed, to help with hemodynamic management.







Goals: SBP <120 & HR 60-80

- Decrease aortic wall stress by lowering the systolic blood pressure, which reduces the possibility of rupture
- Decrease aortic shear stress by minimizing the rate of rise of aortic pressure to decrease the likelihood of dissection propagation

• IV Beta blocker:

Esmolol, metoprolol, labetalol

- Beta-1 selective blocking agent with a short half life.
- Calcium channel blockers if contraindicated
- Decreases the inotropic state of the myocardium and decreases the heart rate
- Calcium Channel Blocker

Nicardipine, Amlodipine

- IV Vasodilator: <u>Sodium nitroprusside</u>
 - Direct arterial vasodilator, short onset and duration of action
- Pain control: Treat symptoms Morphine, Fentanyl

Long Term Medication Management

Recommendations for BP Management in TAA Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR	LOE	Recommendations
1	B-NR	 In patients with TAA and an average systolic BP (SBP) of ≥130 mm Hg or an average diastolic BP (DBP) of ≥80 mm Hg, the use of antihypertensive medications is recommended to reduce risk of cardiovascular events.¹⁻³
COR	LOE	Recommendations
2a	C-LD	2. In patients with TAA, regardless of cause and in the absence of contraindications, use of beta blockers to achieve target BP goals is reasonable. ^{1,4,5}
2a	C-EO	 In patients with TAA, regardless of etiology and in the absence of contraindications, ARB therapy is a reasonable adjunct to beta- blocker therapy to achieve target BP goals.⁶

Recommendation for BP Management in AAA Referenced studies that support the recommendation are summarized in the Online Data Supplement.

COR	LOE	Recommendation
1	B-NR	 In patients with AAA and an average SBP of ≥130 mm Hg, or an average DBP of ≥80 mm Hg, the use of antihypertensive medication is recommended to reduce risk of cardiovascular events.¹⁻³

GOAL: SBP <130/80 mmHg Beta Blocker: (Metoprolol, Carvedilol) HR, SV ARB: (Losartan, Valsartan) SVR, SV

Long Term Management Cont.

Recommendations for Treatment of TAA With Statins		
COR	LOE	Recommendations
2a	C-LD	 In patients with TAA and imaging or clinical evidence of atherosclerosis, statin therapy at moderate or high intensity is reasonable.^{1,2}
2b	C-LD	 In patients with TAA who have no evidence of atherosclerosis, the use of statin therapy may be considered.³⁻⁶

Recommen	Recommendation for Smoking Cessation in AAA		
COR	LOE	Recommendation	
		1. In patients with AAA who smoke ci	

	 In patients with AAA who smoke cigarettes,
LD	smoking cessation efforts are recom-
	mended. ¹⁻⁴

Recommen	ecommendation for Smoking Cessation in TAA		
COR	LOE	Recommendation	
1	C-LD	1. In patients with TAA who smoke cigarettes, smoking cessation efforts are recommended. ¹²	

Recommendations for Treatment of AAA With Statins Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR	LOE	Recommendations
1	B-NR	 In patients with AAA and evidence of aortic atherosclerosis, statin therapy at moderate or high intensity is recommended.¹⁻³
2b	C-LD	 In patients with AAA but no evidence of atherosclerosis, statin therapy may be considered.^{4,5}

1

C

Thank You!



Rita.weise@hoag.org

Hoag Memorial Hospital 949-764-5314

